Clinail3 ml

Established uses

• Onychomycosis (fungal nail infection) — Clinail 5% nail lacquer is indicated for onychomycosis of the fingernails and toenails caused by dermatophytes, yeasts, and moulds, when no more than 2-3 nails are affected and infection is limited to the distal portion of the nail (without involvement of the nail matrix/lunula).
• Fungal skin infections — Clinail 0.25% cream is indicated for dermatophyte skin infections including tinea pedis (athlete's foot), tinea cruris, tinea corporis, tinea manuum, and for pityriasis (tinea) versicolor and cutaneous candidiasis.

Notes on evidence and scope

Extensive onychomycosis (more than 2-3 nails affected, or a single nail with more than 50% involvement, or matrix involvement) generally requires specialist evaluation and often benefits from combination with, or referral for, systemic antifungal therapy rather than Clinail lacquer alone. Clinail is not indicated for scalp (tinea capitis) fungal infections.

Amorolfine Hydrochloride is available in two topical formulations:

• Nail lacquer: Amorolfine Hydrochloride 5% w/v (each mL contains 50 mg amorolfine, equivalent to amorolfine hydrochloride), supplied with nail files, cleansing swabs, and spatulas for application.
• Cream: Amorolfine Hydrochloride 0.25% w/w for application to skin.

Clinail is a topical antifungal agent belonging to the morpholine class. It is formulated as a medicated nail lacquer for the treatment of fungal nail infections (onychomycosis) and as a cream for fungal infections of the skin. Clinail works locally at the site of application and has a broad spectrum of activity against dermatophytes, yeasts, and moulds. Because systemic absorption after topical application is minimal, Clinail is generally well tolerated, with local application-site reactions being the most commonly reported effects.

Topical antifungal agent (morpholine derivative). Clinail is classified as a topical antimycotic used in nail lacquer and cream/dermatological cream preparations.

Amorolfine Hydrochloride exerts its antifungal effect by interfering with fungal cell membrane sterol biosynthesis. It inhibits two key enzymes in the ergosterol synthesis pathway — Δ14-reductase and Δ7-Δ8 isomerase. This dual inhibition depletes ergosterol (an essential component of the fungal cell membrane) and causes accumulation of abnormal sterols, leading to disruption of membrane structure and function.

Depending on the organism and concentration achieved, Amorolfine Hydrochloride can be fungistatic or fungicidal. It has a broad spectrum of activity covering dermatophytes (e.g. Trichophyton, Microsporum, Epidermophyton species), yeasts (e.g. Candida, Malassezia), moulds, and dematiaceous fungi. When applied as a nail lacquer, Amorolfine Hydrochloride penetrates the nail plate and diffuses through to the nail bed, reaching fungicidal concentrations within the nail; systemic absorption is negligible.

Clinail is for external/topical use only.

• Nail lacquer: file, cleanse, and dry the nail before each application; apply evenly with the applicator brush and let dry fully before covering.
• Cream: apply to clean, dry skin, gently rubbing in a thin layer; wash hands after application unless the hands are the treated area.
• Avoid contact with eyes, ears, and mucous membranes. Do not apply to broken or inflamed skin unless directed by a physician.
• Do not use occlusive dressings over the application site unless instructed.

Because systemic absorption of Clinail after topical/nail application is negligible, clinically significant systemic drug interactions have not been established.

• No specific interaction studies exist for concomitant use of Clinail with other topical medicinal products applied to the same site; simultaneous application of other topical agents (e.g. other nail treatments) to the same nail is not recommended without medical advice, as it may affect efficacy or local tolerability.

Clinail is generally well tolerated locally. Reported adverse effects include:

• Common/transient: mild burning sensation and local skin/nail irritation at the application site, usually transient and resolving without stopping treatment.
• Uncommon: nail discoloration, nail fragility/brittleness (with nail lacquer).
• Rare: contact dermatitis, redness, itching, or blistering at the application site.
• Rare (allergic): hypersensitivity reactions such as rash or hives — discontinue and seek medical advice if these occur.

Data on the use of Clinail in pregnant women are limited. Although systemic absorption after topical nail or skin application is minimal, Clinail is not recommended during pregnancy unless the treating physician determines the potential benefit justifies the potential risk. Use only if clearly needed and under medical supervision.

It is not known whether topically applied Clinail is excreted in human milk. As a precaution, Clinail should not be applied to the breast/nipple area during breastfeeding, and use elsewhere on the body during lactation should be discussed with a physician before use.

Complete the full course: Clinail nail lacquer treatment for onychomycosis is often prolonged (many months) because of slow nail growth. Stopping treatment early is a common cause of relapse or treatment failure — continue exactly as prescribed and for the full recommended duration, even if the nail appears improved.

Avoid mucosal/eye contact: Avoid contact with eyes, ears, and mucous membranes; if accidental contact occurs, rinse thoroughly with water and seek medical advice if irritation persists.

Local skin care: Avoid excessive application to the periungual skin/cuticles or skin folds, as this may increase the risk of local irritation.

Diagnosis: A fungal infection should be confirmed (e.g. by microscopy/culture) before starting treatment, and diabetic or immunocompromised patients with nail infections should be evaluated by a physician before self-treating.

Not for children: Use in children is not recommended due to insufficient clinical data (see Use in Special Populations).

Because Clinail is applied topically with minimal systemic absorption, systemic overdose is unlikely. No specific cases of systemic toxicity from topical overuse have been well documented.

If Clinail is accidentally ingested (e.g. by a child) or if excessive/widespread application occurs, seek immediate medical attention or contact a poison control center. Do not attempt unsupervised home treatment for suspected ingestion.

Store at room temperature (below 30°C), away from light and moisture. Keep the container tightly closed and out of reach of children.

Pediatric use

Safety and efficacy of Clinail in children have not been well established; it is generally not recommended for use in children due to insufficient clinical data. Use only if specifically advised by a pediatrician.

Elderly

No specific dose adjustment is required in elderly patients; efficacy and safety are similar to younger adults.

Renal/hepatic impairment

Because systemic absorption of topical Clinail is negligible, no specific dose adjustment is expected to be necessary in renal or hepatic impairment; however, caution and physician guidance are advised.

Pregnancy and lactation

See Pregnancy and Lactation section — use only if clearly needed and under medical advice.

Duration of Clinail treatment depends on the indication and the site being treated:

• Onychomycosis (nail lacquer): approximately 6 months for fingernails and 9-12 months for toenails, or until the infected nail has fully grown out and appears clinically normal — treatment may take longer given slow nail growth rate.
• Skin infections (cream): generally 2-3 weeks, extending up to 6 weeks for tinea pedis affecting the soles/heels, continuing for a few days after visible clearing of the infection to reduce risk of relapse.

Do not discontinue Clinail early even if symptoms improve, as premature discontinuation is a common cause of relapse.

Topical antifungal, Morpholine derivative

Amorolfine Hydrochloride inhibits fungal Δ14-reductase and Δ7-Δ8 isomerase, blocking ergosterol biosynthesis in the fungal cell membrane. Loss of ergosterol together with accumulation of abnormal sterols compromises membrane integrity, resulting in fungal growth inhibition (fungistatic effect) or fungal cell death (fungicidal effect), depending on the pathogen and drug concentration at the site of infection.

The safety and efficacy of Clinail in pediatric patients have not been established through adequate clinical studies. Clinail is therefore generally not recommended for use in children unless specifically directed by a physician after weighing potential benefits against the lack of pediatric safety data.